Pyxis Oncology granted Fast Track designation for PYX-201 monotherapy

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody. PYX-201 is a first-in-concept antibody-drug conjugate that uniquely targets Extradomain-B Fibronectin, a non-cellular structural component within the tumor extracellular matrix, which is highly expressed in various tumor types.